These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 19423276)

  • 21. Left ventricular systolic function in HER2/neu negative breast cancer patients treated with anthracycline chemotherapy: a comparative analysis of left ventricular ejection fraction and myocardial strain imaging over 12 months.
    Stoodley PW; Richards DA; Boyd A; Hui R; Harnett PR; Meikle SR; Byth K; Stuart K; Clarke JL; Thomas L
    Eur J Cancer; 2013 Nov; 49(16):3396-403. PubMed ID: 23937961
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anthracycline-induced cardiotoxicity: clinical course, risk factors, pathogenesis, detection and prevention--review of the literature.
    Wojtacki J; Lewicka-Nowak E; Leśniewski-Kmak K
    Med Sci Monit; 2000; 6(2):411-20. PubMed ID: 11208348
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnosis of anthracycline-induced late cardiomyopathy by exercise-spiroergometry and stress-echocardiography.
    Hauser M; Gibson BS; Wilson N
    Eur J Pediatr; 2001 Oct; 160(10):607-10. PubMed ID: 11686505
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Advanced heart failure therapies for patients with chemotherapy-induced cardiomyopathy.
    Oliveira GH; Qattan MY; Al-Kindi S; Park SJ
    Circ Heart Fail; 2014 Nov; 7(6):1050-8. PubMed ID: 25415958
    [No Abstract]   [Full Text] [Related]  

  • 25. Left ventricular strain and strain rates are decreased in children with normal fractional shortening after exposure to anthracycline chemotherapy.
    Moon TJ; Miyamoto SD; Younoszai AK; Landeck BF
    Cardiol Young; 2014 Oct; 24(5):854-65. PubMed ID: 24044518
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Cardioprotective treatment during adjuvant cancer therapy].
    Gulati G; Heck SL; Ree AH; Gravdehaug B; Røsjø H; Steine K; Bratland Å; Hoffmann P; Geisler J; Omland T
    Tidsskr Nor Laegeforen; 2013 Sep; 133(17):1832-6. PubMed ID: 24042297
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protective effects of carvedilol against anthracycline-induced cardiomyopathy.
    Kalay N; Basar E; Ozdogru I; Er O; Cetinkaya Y; Dogan A; Inanc T; Oguzhan A; Eryol NK; Topsakal R; Ergin A
    J Am Coll Cardiol; 2006 Dec; 48(11):2258-62. PubMed ID: 17161256
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Chemotherapeutics-induced heart failure].
    Paulides M; Wojnowski L
    Med Klin (Munich); 2007 Jul; 102(7):574-8. PubMed ID: 17634876
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [ACE inhibitors in the treatment of ventricular dysfunction caused by cardiotoxic cytostatics].
    Mladosievicová B
    Ceska Slov Farm; 2004 Mar; 53(2):55-60. PubMed ID: 15095572
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy.
    Cardinale D; Colombo A; Lamantia G; Colombo N; Civelli M; De Giacomi G; Rubino M; Veglia F; Fiorentini C; Cipolla CM
    J Am Coll Cardiol; 2010 Jan; 55(3):213-20. PubMed ID: 20117401
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure.
    Tallaj JA; Franco V; Rayburn BK; Pinderski L; Benza RL; Pamboukian S; Foley B; Bourge RC
    J Heart Lung Transplant; 2005 Dec; 24(12):2196-201. PubMed ID: 16364871
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Present risk of anthracycline or radiation-induced cardiac sequelae following therapy of malignancies in children and adolescents.
    Chen C; Heusch A; Donner B; Janssen G; Göbel U; Schmidt KG
    Klin Padiatr; 2009; 221(3):162-6. PubMed ID: 19437364
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biomarkers and early detection of late onset anthracycline-induced cardiotoxicity in children.
    Sherief LM; Kamal AG; Khalek EA; Kamal NM; Soliman AA; Esh AM
    Hematology; 2012 May; 17(3):151-6. PubMed ID: 22664114
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardioprotective role of β-blockers and angiotensin antagonists in early-onset anthracyclines-induced cardiotoxicity in adult patients: a systematic review and meta-analysis.
    Yun S; Vincelette ND; Abraham I
    Postgrad Med J; 2015 Nov; 91(1081):627-33. PubMed ID: 26399268
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anthracycline-induced cardiomyopathy.
    Keefe DL
    Semin Oncol; 2001 Aug; 28(4 Suppl 12):2-7. PubMed ID: 11552224
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interventions for preventing cardiomyopathy due to anthracyclines: a Bayesian network meta-analysis.
    Abdel-Qadir H; Ong G; Fazelzad R; Amir E; Lee DS; Thavendiranathan P; Tomlinson G
    Ann Oncol; 2017 Mar; 28(3):628-633. PubMed ID: 28028033
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Signal-averaged electrocardiography in children with anthracycline-induced cardiomyopathy.
    Vaksmann G; Gutierrez R; Duhamel A; Nelken B; Francart C; Kouakam C; Mazingue F; Rey C
    Pediatr Cardiol; 2001; 22(6):494-8. PubMed ID: 11894153
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anthracycline-Induced Cardiomyopathy in Adults.
    Tan TC; Neilan TG; Francis S; Plana JC; Scherrer-Crosbie M
    Compr Physiol; 2015 Jul; 5(3):1517-40. PubMed ID: 26140726
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    Laursen AH; Thune JJ; Hutchings M; Hasbak P; Kjaer A; Elming MB; Ripa RS
    Clin Physiol Funct Imaging; 2018 Mar; 38(2):176-185. PubMed ID: 28251781
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early diagnosis of chemotherapy-induced cardiomyopathy: a prospective tissue Doppler imaging study.
    Nagy AC; Cserép Z; Tolnay E; Nagykálnai T; Forster T
    Pathol Oncol Res; 2008 Mar; 14(1):69-77. PubMed ID: 18347931
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.